AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Amneal Pharmaceuticals In... (AMRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.87

0.02 (0.25%)

At close: Feb 20, 2025, 3:59 PM

7.87

0.06%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	7.65
Market Cap	3.63B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.86
PE Ratio (ttm)	-9.15
Forward PE	n/a
Analyst	Buy

Ask	8.01
Volume	794,708
Avg. Volume (20D)	1,101,098
Open	7.81
Previous Close	7.85
Day's Range	7.70 - 7.88
52-Week Range	5.01 - 9.47
Beta	undefined

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation produc...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 7, 2018

Employees 7,850

Stock Exchange NYSE

Ticker Symbol AMRX

Website https://www.amneal.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AMRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 27.15% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Amneal Pharmaceuticals Inc. is scheduled to release its earnings on Feb 28, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+4.71%

Amneal Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

3 months ago

+5.38%

Amneal Pharmaceuticals shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $9 to $11.

News

2 weeks ago · zacks.com

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago · zacks.com

Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know

The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

2 weeks ago · zacks.com

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.

3 weeks ago · businesswire.com

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.

1 month ago · zacks.com

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

1 month ago · zacks.com

Amneal (AMRX) Upgraded to Strong Buy: Here's Why

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 months ago · businesswire.com

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.